Zobrazeno 1 - 10
of 20
pro vyhledávání: '"MedDRA, Medical Dictionary for Regulatory Activities"'
Autor:
Stephen J. Thomas, John L. Perez, Stephen P. Lockhart, Subramanian Hariharan, Nicholas Kitchin, Ruth Bailey, Katherine Liau, Eleni Lagkadinou, Özlem Türeci, Ugur Şahin, Xia Xu, Kenneth Koury, Samuel S. Dychter, Claire Lu, Teresa C. Gentile, William C. Gruber
Publikováno v:
Vaccine
Introduction Individuals with an underlying malignancy have high risk of poor COVID-19 outcomes. In clinical trials, COVID-19 vaccines were safe and efficacious against infection, hospitalization, and death, but most trials excluded participants with
Autor:
Jin Gyu Jung, Sunghyun Kim, Bum Soo Kim, Anca Streinu-Cercel, Oana Săndulescu, Da Bee Jeon, Adrian Streinu-Cercel, Seul Gi Lee, Sang Joon Lee, Yeon Sook Kim, Yeo Jin Lee, Jin Yong Kim, Yeon Mi Lee, Min Kyung Kim, Jae-Hyeong Park, Jang Hee Hong, Jeong Eun Park, Young Rock Jang, Na Hyun Jung
Publikováno v:
Clinical Therapeutics
PURPOSE: Neutralizing antibodies can reduce SARS-CoV-2 cellular entry, viral titers, and pathologic damage. CT-P59 (regdanvimab), a SARS-CoV-2 neutralizing monoclonal antibody, was examined in 2 randomized, double-blind, placebo-controlled, single as
Publikováno v:
Acta Pharmaceutica Sinica. B
Acta Pharmaceutica Sinica B, Vol 11, Iss 12, Pp 3857-3868 (2021)
Acta Pharmaceutica Sinica B, Vol 11, Iss 12, Pp 3857-3868 (2021)
Drug-induced liver injury (DILI) is a leading reason for preclinical safety attrition and post-market drug withdrawals. Drug-induced mitochondrial toxicity has been shown to play an essential role in various forms of DILI, especially in idiosyncratic
Publikováno v:
eNeurologicalSci, Vol 25, Iss, Pp 100374-(2021)
eNeurologicalSci
eNeurologicalSci
To date, efficacy data on botulinum toxin type B (rimabotulinumtoxinB) in patients with cervical dystonia (CD) previously treated with botulinum toxin type A in a large population are lacking; thus, we aimed to evaluate type B efficacy in this patien
Autor:
Pauline Lory, Jeffrey Lombardi, Clémence Lacroix, Paola Sanchez-Pena, Serena Romani, Aurélie Grandvuillemin
Publikováno v:
Therapie
Aims: At the beginning of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, there were no clinically-tested medications for the effective treatment of coronavirus disease. In this context, on 5 March 2020, the French Public H
Publikováno v:
Journal of the American Academy of Dermatology
Background Respiratory tract infections (RTIs) and interstitial lung disease (ILD) secondary to interleukin (IL)-12/23 or IL-23 antagonists have been reported in autoimmune diseases. Objective To assess the risk of RTIs and non-infectious ILD with th
Publikováno v:
JACC: CardioOncology
Ye, J Z, Hansen, F B, Mills, R W & Lundby, A 2021, ' Oncotherapeutic Protein Kinase Inhibitors Associated With Pro-Arrhythmic Liability ', JACC: CardioOncology, vol. 3, no. 1, pp. 88-97 . https://doi.org/10.1016/j.jaccao.2021.01.009
Ye, J Z, Hansen, F B, Mills, R W & Lundby, A 2021, ' Oncotherapeutic Protein Kinase Inhibitors Associated With Pro-Arrhythmic Liability ', JACC: CardioOncology, vol. 3, no. 1, pp. 88-97 . https://doi.org/10.1016/j.jaccao.2021.01.009
Background Ibrutinib is a protein kinase inhibitor that has been widely successful in treating multiple common variations of B-cell cancers. However, an unfortunate side effect of ibrutinib is that it predisposes patients to development of atrial fib
Publikováno v:
Contemporary Clinical Trials Communications
Contemporary Clinical Trials Communications, Vol 4, Iss C, Pp 199-207 (2016)
Contemporary Clinical Trials Communications, Vol 4, Iss C, Pp 199-207 (2016)
Background Patient-level data are available for 11 randomized, controlled, Phase III/Phase IV solifenacin clinical trials. Methods Meta-analyses were conducted to interrogate the data, to broaden knowledge about solifenacin and overactive bladder (OA
Autor:
K. Kluehr, D. Lee, D. Wessiepe, Tim Higenbottam, Oliver Pfaar, Piotr Kuna, A. Wade, Matthew D. Heath, J. Raab, K. Gunawardena, Matthias F. Kramer, S. Lassmann, Murray A. Skinner, Werner Aberer, Ludger Klimek, P.J. de Kam, Stefan Zielen
Publikováno v:
World Allergy Organization Journal, Vol 12, Iss 11, Pp-(2019)
The World Allergy Organization Journal
The World Allergy Organization Journal
Background: Pollinex Quattro Grass (PQ Grass) is an effective, well-tolerated, short pre-seasonal subcutaneous immunotherapy to treat seasonal allergic rhinoconjunctivitis (SAR) due to grass pollen. In this Phase II study, 4 cumulative doses of PQ Gr
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.